机构:[1]Department of Pathology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Department of Ophthalmology and Research Laboratory of Ophthalmology and Vision Sciences, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
National Natural Science Foundation of China
(NSFC), Grant/Award Numbers: 81872108,
81872107, 81572541, 81572540
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|3 区医学
小类|3 区泌尿学与肾脏学4 区内分泌学与代谢
最新[2023]版:
大类|3 区医学
小类|3 区泌尿学与肾脏学4 区内分泌学与代谢
第一作者:
第一作者机构:[1]Department of Pathology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
通讯作者:
通讯机构:[1]Department of Pathology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.[*1]Department of Pathology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714):
Xu Yunyi,Xu Miao,Li Xinglan,et al.SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression[J].The Prostate.2022,doi:10.1002/pros.24476.
APA:
Xu Yunyi,Xu Miao,Li Xinglan,Weng Xin,Su Zhengzheng...&Zhou Qiao.(2022).SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression.The Prostate,,
MLA:
Xu Yunyi,et al."SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression".The Prostate .(2022)